William E. Boden

William E. Boden

Auto-generated profile, based on publicly available information

William E. Boden

VA New England Healthcare System, Boston, MA (W.E.B.).

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in Circulation
Verified
Journal Article
Open access
PDF file
AMArjun Majithia
Arjun Majithia
DBDeepak L Bhatt
Deepak L Bhatt
AFAllon N Friedman
Allon N Friedman
MMMichael Miller
Michael Miller
GSGabriel Steg
Gabriel Steg
CBChristie M. Ballantyne
Christie M. Ballantyne
Background: Chronic kidney disease is associated with adverse outcomes among patients with established cardiovascular disease (CVD) or diabetes. Commonly used medications to treat CVD are less effective among patients with reduced kidney function. Methods: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was a multicenter, double-blind, placebo-controlled trial that randomly assigned statin-treated patients with elevated triglycerides (135–499 mg/dL) who had CVD or diabetes and 1 additional risk factor to treatment with icosapent ethyl (4 g daily) or placebo. Patients from REDUCE-IT were categorized by prespecified estimated glomerular filtration rate (eGFR) categories to analyze the effect of icosapent ethyl on the primary end point (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) and key secondary end point (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Results: Among the 8179 REDUCE-IT patients, median baseline eGFR was 75 mL·min –1 ·1.73 m –2 (range, 17–123 mL·min –1 ·1.73 m –2 ). There were no meaningful changes in median eGFR for icosapent ethyl versus placebo across study visits. Treatment with icosapent ethyl led to consistent reduction in both the primary and key secondary composite end points across baseline eGFR categories. Patients with eGFR <60 mL·min –1 ·1.73 m –2 treated with icosapent ethyl had the largest absolute and similar relative risk reduction for the primary composite end point (icosapent ethyl versus placebo, 21.8% versus 28.9%; hazard ratio [HR], 0.71 [95% CI, 0.59–0.85]; P =0.0002) and key secondary composite end point (16.8% versus 22.5%; HR 0.71 [95% CI, 0.57–0.88]; P =0.001). The numeric reduction in cardiovascular death was greatest in the eGFR <60 mL·min –1 ·1.73 m –2 group (icosapent ethyl: 7.6%; placebo: 10.6%; HR, 0.70 [95% CI, 0.51–0.95]; P =0.02). Although patients with eGFR <60 mL·min –1 ·1.73 m –2 treated with icosapent ethyl had the highest numeric rates of atrial fibrillation/flutter (icosapent ethyl: 4.2%; placebo 3.0%; HR 1.42 [95% CI, 0.86–2.32]; P =0.17) and serious bleeding (icosapent ethyl: 5.4%; placebo 3.6%; HR, 1.40 [95% CI, 0.90–2.18]; P =0.13), HRs for atrial fibrillation/flutter and serious bleeding were similar across eGFR categories ( P -interaction for atrial fibrillation/flutter=0.92; P -interaction for serious bleeding=0.76). Conclusions: In REDUCE-IT, icosapent ethyl reduced fatal and nonfatal ischemic events across the broad range of baseline eGFR categories. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01492361

30 January 2023 in JACC
Verified
Journal Article
Closed access
WBWilliam E. Boden
William E. Boden
MMMario Marzilli
Mario Marzilli
FCFilippo Crea
Filippo Crea
GMG.B. John Mancini
G.B. John Mancini
WWWilliam S. Weintraub
William S. Weintraub
JKJuan Carlos Kaski
Juan Carlos Kaski

23 December 2019 in European Heart Journal
Verified
Journal Article
Open access
WBWilliam E Boden
William E Boden
DBDeepak L Bhatt
Deepak L Bhatt
PTPeter P Toth
Peter P Toth
KRKausik K Ray
Kausik K Ray
MCM John Chapman
M John Chapman
TLThomas F Lüscher
Thomas F Lüscher
The aims of this clinical review are to: (i) highlight the importance of elevated baseline triglycerides (TG) in the setting of well-controlled low-density lipoprotein cholesterol (LDL-C) on statins as a major contributor to residual atherosclerotic cardiovascular disease (ASCVD) risk, particularly among patients with type 2 diabetes mellitus, metabolic syndrome, and obesity whose distinctive lipid phenotype cannot be optimally treated with LDL-C reduction therapy alone; (ii) describe the findings and clinical implications of the landmark REDUCE-IT trial in which ethyl eicosapentaenoic acid significantly improved ASCVD outcomes. While many genetic studies have shown that elevated TG are an independent causal factor for ASCVD, prior placebo-controlled trials using niacin, fibrates, omega-3 fatty acids, and dietary supplement fish oil preparations have failed to demonstrate significant CV event reduction when added to statin therapy. In contrast, the REDUCE-IT trial in 8179 participants showed convincingly that the administration of 4 g daily of icosapent ethyl (an ethyl ester of eicosapentaenoic acid) in patients at high risk for ASCVD with increased levels of baseline TG [median value, 2.44 mmol/L (216.0 mg/dL)] but well-controlled LDL-C [median value, 1.94 mmol/L (75.0 mg/dL)] reduced significantly incident events across both the trial primary endpoint and multiple prespecified secondary endpoints, including cardiovascular death, as well as both subsequent and total primary endpoint and key secondary endpoint events. Icosapent ethyl unequivocally contributed to ASCVD event reduction over and above statin therapy. The REDUCE-IT trial results should alter our approach to managing a growing population of hypertriglyceridaemic patients whose lipid phenotype requires more intensive treatment beyond LDL-C lowering alone.

1 June 2020 in American Heart Journal
Verified
Journal Article
Closed access
WBWilliam E. Boden
William E. Boden
MMMichael G. Miller
Michael G. Miller
RMRuth McBride
Ruth McBride
CHChristopher Harvey
Christopher Harvey
MSMichael C. Snabes
Michael C. Snabes
JPJeffrey L. Probstfield
Jeffrey L. Probstfield

9 January 2013 in JAMA
Verified
Journal Article
Closed access
PDF file
WBWilliam E. Boden
William E. Boden
BFBarry A. Franklin
Barry A. Franklin
NWNanette K. Wenger
Nanette K. Wenger
Exercise was recently described as “a miracle drug” that can benefit every part of the body and substantially extend lifespan.” The authors suggested that the c

1 March 2016 in American Heart Journal
Verified
Journal Article
Closed access
SASubroto Acharjee
Subroto Acharjee
KTKoon K. Teo
Koon K. Teo
AJAlice K. Jacobs
Alice K. Jacobs
PHPamela M. Hartigan
Pamela M. Hartigan
KBKulpreet Barn
Kulpreet Barn
WBWilliam E. Boden
William E. Boden